MedTrace Logo

Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH

NCT05120687 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-11-15

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of corticosteroidcombining noncorticosteroid systemic immunomodulatory therapy (NCSIT) for the treatment of Vogt Koyanagi Harada disease (VKH).

Conditions

  • Vogt Koyanagi Harada Disease (VKH)

Interventions

DRUG

noncorticosteroid systemic immunomodulatory therapy (NCSIT)

Patients in corticosteroid + NCSIT group will receive systemic corticosteroids combined with Methotrexate 15mg/week or Adalimumab 40mg /2weeks or Mycophenolate Mofetil 1g/day or Cyclosporin 50mg-100mg/day or cyclophosphamide 10mg/kg on two consecutive days every 2 weeks.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2024-10-06
Completion
2025-10-06

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05120687 on ClinicalTrials.gov